Pharmaceutical composition for use as a contraceptive

US6787531B1 · kind B1 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Juergen Hilman · Berlin, DE
• Wolfgang Heil · Berlin, DE
• Ralph Lipp · Berlin, DE
• Renate Heithecker · Berlin, DE
• Michael Huempel · Berlin, DE
• Johannes Tack · Berlin, DE

Key dates

• Filing date: Aug 31, 2000
• Grant date: Sep 7, 2004
• Expiry date: Aug 31, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/567
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A pharmaceutical composition comprises, as a first active agent, 6&bgr;,7&bgr;;15&bgr;,16&bgr;-dimethylene-3-oxo-17&agr;-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17&agr;-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients.In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing ethinylestradiol alone.